Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yu Cao, Huajian Zhu, Ruoyu He, Limin Kong, Jiaan Shao, Rangxiao Zhuang, Jianjun Xi & Jiankang Zhang. (2020) Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer. Drug Design, Development and Therapy 14, pages 4327-4342.
Read now
Read now
Tanya Chandra & Rohit Aggarwal. (2020) Clinical trials and novel therapeutics in dermatomyositis. Expert Opinion on Emerging Drugs 25:3, pages 213-228.
Read now
Read now
Articles from other publishers (16)
Yunxuan Li, Guanglei Nan, Xianxin Hou, Yechao Yan, Yajun Yang, Ying Yang, Ke Li & Zhiyan Xiao. (2023) Non-peptidic immunoproteasome β5i-selective inhibitor as potential treatment for idiopathic pulmonary fibrosis: Virtual screening, hit evolution and lead identification. European Journal of Medicinal Chemistry 261, pages 115856.
Crossref
Crossref
Grazia R. Tundo, Paolo Cascio, Danilo Milardi, Anna Maria Santoro, Grazia Graziani, Pedro Miguel Lacal, Alessio Bocedi, Francesco Oddone, Mariacristina Parravano, Andrea Coletta, Massimo Coletta & Diego Sbardella. (2023) Targeting immunoproteasome in neurodegeneration: A glance to the future. Pharmacology & Therapeutics 241, pages 108329.
Crossref
Crossref
Po-Wen Tu, Jie-Siang Chiu, Chih Lin, Chih-Cheng Chien, Feng-Chia Hsieh, Ming-Che Shih & Yu-Liang Yang. (2022) Evaluation of the Antifungal Activities of Photorhabdus akhurstii and Its Secondary Metabolites against Phytopathogenic Colletotrichum gloeosporioides. Journal of Fungi 8:4, pages 403.
Crossref
Crossref
Guanglei Nan, Lei Huang, Yunxuan Li, Yajun Yang, Ying Yang, Ke Li, Fangfang Lai, Xiaoguang Chen & Zhiyan Xiao. (2022) Identification of N, C-capped di- and tripeptides as selective immunoproteasome inhibitors. European Journal of Medicinal Chemistry 234, pages 114252.
Crossref
Crossref
Vasudha TandonRuturajsinh M. Vala, Albert ChenRobert L. SahHitendra M. Patel, Michael C. PirrungSourav Banerjee. (2022)
Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration
in vivo
. Bioscience Reports 42:2.
Crossref
Crossref
Grazia R. Tundo, Diego Sbardella, Francesco Oddone, Anna A. Kudriaeva, Pedro M. Lacal, Alexey A. BelogurovJr.Jr., Grazia Graziani & Stefano Marini. (2021) At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention. Cancers 13:19, pages 4852.
Crossref
Crossref
Min Jae Lee, Deepak Bhattarai, Hyeryung Jang, Ahreum Baek, In Jun Yeo, Seongsoo Lee, Zachary Miller, Sukyeong Lee, Jin Tae Hong, Dong-Eun Kim, Wooin Lee & Kyung Bo Kim. (2021) Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer’s Disease. Journal of Medicinal Chemistry 64:15, pages 10934-10950.
Crossref
Crossref
Levente Kollár, Martina Gobec, Bence Szilágyi, Matic Proj, Damijan Knez, Péter Ábrányi-Balogh, László Petri, Tímea Imre, Dávid Bajusz, György G. Ferenczy, Stanislav Gobec, György M. Keserű & Izidor Sosič. (2021) Discovery of selective fragment-sized immunoproteasome inhibitors. European Journal of Medicinal Chemistry 219, pages 113455.
Crossref
Crossref
Eva Shannon Schiffrer, Matic Proj, Martina Gobec, Luka Rejc, Andrej Šterman, Janez Mravljak, Stanislav Gobec & Izidor Sosič. (2021) Synthesis and Biochemical Evaluation of Warhead-Decorated Psoralens as (Immuno)Proteasome Inhibitors. Molecules 26:2, pages 356.
Crossref
Crossref
Piotr Karabowicz, Adam Wroński, Halina Ostrowska, Georg Waeg, Neven Zarkovic & Elżbieta Skrzydlewska. (2020) Reduced Proteasome Activity and Enhanced Autophagy in Blood Cells of Psoriatic Patients. International Journal of Molecular Sciences 21:20, pages 7608.
Crossref
Crossref
Deepak Bhattarai, Min Jae Lee, Ahruem Baek, In Jun Yeo, Zachary Miller, Yu Mi Baek, Sukyeong Lee, Dong-Eun Kim, Jin Tae Hong & Kyung Bo Kim. (2020) LMP2 Inhibitors as a Potential Treatment for Alzheimer’s Disease. Journal of Medicinal Chemistry 63:7, pages 3763-3783.
Crossref
Crossref
Kaja Rožman, Evan M. Alexander, Eva Ogorevc, Krištof Bozovičar, Izidor Sosič, Courtney C. Aldrich & Stanislav Gobec. (2020) Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome. Molecules 25:6, pages 1305.
Crossref
Crossref
Jianjun Xi, Rangxiao Zhuang, Limin Kong, Ruoyu He, Huajian Zhu & Jiankang Zhang. (2019) Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases. European Journal of Medicinal Chemistry 182, pages 111646.
Crossref
Crossref
Nicolas Albornoz, Hianara Bustamante, Andrea Soza & Patricia Burgos. (2019) Cellular Responses to Proteasome Inhibition: Molecular Mechanisms and Beyond. International Journal of Molecular Sciences 20:14, pages 3379.
Crossref
Crossref
Daqiang Li, Xiaotuan Zhang, Xiaodong Ma, Lei Xu, Jianjun Yu, Lixin Gao, Xiaobei Hu, Jiankang Zhang, Xiaowu Dong, Jia Li, Tao Liu, Yubo Zhou & Yongzhou Hu. (2018) Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors. Journal of Medicinal Chemistry 61:20, pages 9177-9204.
Crossref
Crossref
Deepak Bhattarai, Min Jae Lee, Ahruem Baek, Zi Soo Yoo, Zachary Miller, Yu Mi Baek, In Jun Yeo, Jin Tae Hong, Sukyeong Lee, Wooin Lee, Dong-Eun Kim & Kyung Bo Kim. (2019) CNS-penetrant LMP2 Inhibitors as Potential Therapies for Age-related Macular Degeneration. SSRN Electronic Journal.
Crossref
Crossref